Abstracts tagged "hyperuricemia"

Abstract Number: 159 • 2012 ACR/ARHP Annual Meeting
Clinical Efficacy Outcomes with up to 3 Years of Pegloticase Treatment for Refractory Chronic Gout
Michael A. Becker¹, Herbert S. B. Baraf², Robert A. Yood³, Aileen M. Dillon⁴, Janitzia Vazquez-Mellado⁵, Faith D. Ottery⁶, Dinesh Khanna⁷ and John S. Sundy⁸, ¹Medicine, University of Chicago, Chicago, IL, ²Arthritis & Rheumatism Associates, Wheaton, MD, ³Reliant Medical Group, Worcester, MA, ⁴Rheumatology Section, Kaiser Foundation Hospital, San Francisco, CA, ⁵Rheumatology, Hospital General de Mexico, Mexico city, Mexico, ⁶Medical Affairs, Savient Pharmaceuticals, Inc., East Brunswick, NJ, ⁷Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁸Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
Background/Purpose: Pegloticase, a recombinant modified mammalian uricase conjugated to mPEG, was approved for use in refractory chronic gout in the US in 2010. The Phase…
Abstract Number: 160 • 2012 ACR/ARHP Annual Meeting
Pegloticase Long-Term Safety: Data From the Open-Label Extension Trial
Michael A. Becker¹, Herbert S. B. Baraf², Robert A. Yood³, Aileen M. Dillon⁴, Janitzia Vazquez-Mellado⁵, Faith D. Ottery⁶, Dinesh Khanna⁷ and John S. Sundy⁸, ¹Medicine, University of Chicago, Chicago, IL, ²Arthritis & Rheumatism Associates, Wheaton, MD, ³Reliant Medical Group, Worcester, MA, ⁴Rheumatology Section, Kaiser Foundation Hospital, San Francisco, CA, ⁵Rheumatology, Hospital General de Mexico, Mexico city, Mexico, ⁶Medical Affairs, Savient Pharmaceuticals, Inc., East Brunswick, NJ, ⁷Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁸Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
Background/Purpose: Pegloticase is a recombinant modified mammalian uricase conjugated to mPEG and approved for treatment of refractory chronic gout. Pegloticase safety was evaluated during 2…
Abstract Number: 140 • 2012 ACR/ARHP Annual Meeting
Patients That Continue to Flare Despite Apparent Optimal Urate Lowering Therapy
Dinesh Khanna¹, Puja Khanna², David Hagerty³, Chris Storgard⁴, Robert Mischler⁵ and Robert Morlock⁵, ¹Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Division of Rheumatology/Dept. of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, ³Medical, Ardea Bioscience, San Diego, CA, ⁴4939 Directors Place, Ardea Bioscience, San Diego, CA, ⁵Ardea Bioscience, San Diego, CA
Background/Purpose: Gout is a common inflammatory arthritis and its worldwide prevalence is increasing. The purpose of this study is to describe physician, patient and treatment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].